Results from Phase III trials of Novartis' investigational once-daily bronchodilator QAB149 for chronic obstructive pulmonary disease (COPD) have shown significant improvements in lung function.
At 12 weeks of treatment, patients treated with QAB149 showed significantly increased lung function while further new data showed that a higher proportion of patients treated with QAB149 achieved significant improvement in breathlessness compared to tiotropium1.
Novartis Pharma global head of development Trevor Mundel said that QAB149 has the potential to be recognised as the best bronchodilator for COPD.
"The treatment is capable of providing patients with significantly greater lung function improvement and reductions in breathlessness compared to other bronchodilators," Mundel said.
If approved, QAB149 would be the first once-daily bronchodilator to combine clinically relevant 24-hour bronchodilation with onset of action within five minutes.
QAB149 is undergoing regulatory review in the EU, US and other countries around the world for the treatment of COPD.
COPD is a progressive, life-threatening respiratory disease that affects 210 million people worldwide.